Meloxicam Tablet
Product Images NDC 72865-333

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 72865-333). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

15-100 (15 100)

Label for Meloxicam Tablets USP 15 mg oral tablets by XL Care Pharmaceuticals, Inc. The label indicates 100 tablets in the package with Rx only status. It includes storage instructions, manufacturer details (Ascent Pharmaceuticals, Inc.), and a barcode with NDC 72865-333-01.*

FDA Label Image

15-1000 (15 1000)

Label for Meloxicam Tablets USP 15 mg by XL Care Pharmaceuticals Inc. The label indicates 1000 tablets per container, NDC 72865-333-10, with storage instructions at 20° to 25°C and dosage information to read accompanying prescribing information. The product is Rx only, manufactured by Ascent Pharmaceuticals for XL Care Pharmaceuticals.*

FDA Label Image

15-90 (15 90)

This image shows the label for Meloxicam Tablets USP 15 mg by XLCare Pharmaceuticals, Inc. It includes 90 tablets in a prescription oral dosage form. The label displays storage instructions, dosage guidance, manufacturer information, and a barcode, with a clear emphasis on the 15 mg strength.*

FDA Label Image

7.5-100 (7.5 100)

Label for Meloxicam Tablets USP 7.5 mg oral tablets by XLcare Pharmaceuticals, Inc. The package contains 100 tablets. The label includes storage instructions, dispensing guidelines, and manufacturer information with NDC 72865-332-01. It notes the product is prescription only and includes pharmacist dispensing instructions.*

FDA Label Image

7.5-1000 (7.5 1000)

Label for Meloxicam Tablets USP 7.5 mg oral tablets by XLCare Pharmaceuticals, Inc. The label shows a package of 1000 tablets for prescription use only. Storage instructions and manufacturer details for Ascent Pharmaceuticals, Inc. and XLCare Pharmaceuticals, Inc. are included, along with a barcode and revision date.*

FDA Label Image

7.5-90 (7.5 90)

Meloxicam Tablets USP 7.5 mg oral tablets label by XLCare Pharmaceuticals, Inc. The label indicates a package of 90 tablets, Rx only, with storage instructions and manufacturer details. The NDC 72865-332-90 is printed along with a barcode and revision date 09/2025.*

FDA Label Image

Mg1 (Mg1)

Text panel from the MELOXICAM tablet prescribing information discussing warnings related to NSAID use before or after heart surgery, specifically coronary artery bypass graft (CABG), and risks following a recent heart attack. It advises patients on the increased risk of heart attack associated with NSAID use in these conditions.*

FDA Label Image

Mg2 (Mg2)

A partial text panel listing risk factors for ulcers or bleeding associated with NSAID use, including history of stomach ulcers, corticosteroid or anticoagulant use, increasing NSAID doses, older age, smoking, alcohol use, poor health, and advanced liver disease. The text is in black on a white background.*

FDA Label Image

Mg3 (Mg3)

This image shows a text panel containing part of the prescribing information or directions for meloxicam tablets. The visible text includes bullet points advising to take the medication exactly as prescribed, at the lowest dose possible for treatment, and for the shortest time needed. The text is black on white background with standard formatting.*

FDA Label Image

Mg4 (Mg4)

Text panel showing a warning section listing serious side effects that require immediate medical attention for a meloxicam tablet, including shortness of breath, chest pain, weakness on one side of the body, slurred speech, and swelling of the face or throat. The text is part of a medication guide or safety information leaflet for meloxicam tablets.*

FDA Label Image

Mg5 (Mg5)

This image shows a segment of a drug facts or safety information panel listing side effects and symptoms such as nausea, diarrhea, itching, yellowing skin or eyes, vomiting blood, unusual weight gain, skin rash or blisters, and swelling of extremities. The text is presented as bullet points in English.*

FDA Label Image

Structural (Structural Formula)

Chemical structure diagram of meloxicam, showing its molecular composition and arrangement of atoms including sulfur, oxygen, nitrogen, and carbon atoms in the structure.*

FDA Label Image

Table 1a (Table 1a)

A data table summarizing adverse event percentages occurring in 2% or more of Meloxicam patients during a 12-week osteoarthritis placebo- and active-controlled trial. It compares events across four groups: Placebo, Meloxicam 7.5 mg daily, Meloxicam 15 mg daily, and Diclofenac 100 mg daily, covering categories like gastrointestinal, body as a whole, central and peripheral nervous system, respiratory, and skin events.*

FDA Label Image

Table 1b (Table 1b)

A table presenting adverse events occurring in 2% or more of patients treated with meloxicam (7.5 mg daily and 15 mg daily) compared to placebo in two 12-week rheumatoid arthritis placebo-controlled trials. Categories include gastrointestinal disorders, general disorders, infections, musculoskeletal disorders, nervous system disorders, and skin disorders with corresponding percentages for each group.*

FDA Label Image

Table 2.1 (Table 2.1)

A table listing various adverse reactions associated with meloxicam categorized by body system including cardiovascular, central and peripheral nervous system, gastrointestinal, hematologic, respiratory, psychiatric, and others. The table details specific symptoms such as angina pectoris, convulsions, colitis, leukopenia, asthma, anxiety, and renal failure among others.*

FDA Label Image

Table 2 (Table 2)

A data table showing adverse events occurring in 2% or more of Meloxicam patients during 4 to 6 weeks and 6 months active-controlled osteoarthritis trials. The table compares percentages of various gastrointestinal, body, nervous system, hematologic, musculoskeletal, psychiatric, respiratory, skin, and urinary adverse events for 7.5 mg and 15 mg daily doses of Meloxicam.*

FDA Label Image

Table 3.1 (Table 3.1)

A text panel detailing drug interaction warnings and clinical impact for meloxicam with lithium, methotrexate, cyclosporine, NSAIDs and salicylates, and pemetrexed. It outlines risks such as increased toxicity and recommendations for patient monitoring and dosing interruptions during concurrent use of meloxicam with these drugs.*

FDA Label Image

Table 3 (Table 3)

A table titled "Clinically Significant Drug Interactions with Meloxicam" lists drugs that interfere with hemostasis, including aspirin, ACE inhibitors, angiotensin receptor blockers, beta-blockers, and diuretics. For each drug class, it summarizes clinical impacts such as increased bleeding risk and altered drug efficacy, alongside interventions like monitoring patients and hydration recommendations.*

FDA Label Image

Image Description (Table 4)

A data table titled 'Single Dose and Steady-State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam,' presenting pharmacokinetic metrics such as Cmax, Tmax, half-life, clearance, and volume of distribution across different populations, including healthy adults, elderly males and females, as well as patients with renal failure and hepatic insufficiency using 7.5 mg tablets and 15 mg capsules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.